Using the Scaffold of FDA-Approved Drugs with Trypanocidal Activity to Identify New Anti-Trypanosoma cruzi Agents: An In Silico and In Vitro Approach
Molecules · 17.04.2026 · 31 (8) · 1327
DOI: 10.3390/molecules31081327 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, online erschienen am 17.04.2026. Verfasst von Lenci K Vázquez-Jiménez und 9 weiteren Autor:innen. Beteiligte Einrichtung: Laboratorio de Biotecnología Farmacéutica, Centro de Biotecnología Genómica, Instituto Politécnico Nacional, Reynosa 88710, Mexico. Hauptthemen laut MEDLINE: Trypanosoma cruzi, Trypanocidal Agents, Drug Repositioning. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Secretaria de Investigacion y Posgrado del Instituto Politecnico Nacional, Secretaría de Investigación y Posgrado del Instituto Politécnico Nacional.
Abstract (Originalsprache)
Chagas disease affects millions of people worldwide, including those in Latin America. The only drugs available for its treatment are benznidazole and nifurtimox. However, these drugs present high toxicity and limited efficacy. Therefore, the search for new treatments continues. In this regard, computer-assisted drug design has been implemented in scientific research for drug repurposing, allowing for reduced costs and time. Therefore, the objective of this work was to search for analogs of FDA-approved drugs with activity against Trypanosoma cruzi through ligand-based virtual screening and their biological evaluation against blood trypomastigotes. The compound TD-095 (LC50 = 48.60 and 13.75 µM), a ketanserin analogue, TS-936 (LC50 = 71.55 and 37.54 µM), a terfenadine analogue, and TD-831 (LC50 = 75.94 and 26.17 µM), a sulfasalazine analogue, were considered as potential trans-sialidase inhibitors; TIM-967 (LC50 = 69.70 and 39.69 µM) and LK-284 (LC50 = 116.7 and 82.29 µM), two sulfonylurea analogues, were considered as potential triosephosphate isomerase inhibitors, showing better trypanocidal activity against NINOA and INC-5 strains, respectively, than the reference drugs. Molecular dynamics simulations predicted the stability of the compounds in complex with their respective proteins. Finally, the ADMET predictive analysis showed favorable properties for the compounds. These results support continued research into new agents against Trypanosoma cruzi, using structures of drugs already approved by the FDA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratorio de Biotecnología Farmacéutica, Centro de Biotecnología Genómica, Instituto Politécnico Nacional, Reynosa 88710, Mexico.
- Secretaría de Ciencia, Humanidades, Tecnología e Innovación (SECIHTI), Ciudad de México 03940, Mexico.
- Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Ciudad de México 11340, Mexico.
- Departamento de Ciencias Médicas y de la Vida, Centro Universitario de la Ciénega (CUCIÉNEGA), Universidad de Guadalajara, Av. Universidad 1115, Lindavista, Ocotlán 47820, Mexico.
- Laboratorio de Estudios Epidemiológicos, Clínicos, Diseños Experimentales e Investigación, Facultad de Ciencias Químicas, Universidad Autónoma "Benito Juárez" de Oaxaca, Avenida Universidad S/N, Ex Hacienda Cinco Señore…
ORCID-Profile: Lenci K Vázquez-Jiménez, Timoteo Delgado-Maldonado, Guadalupe Avalos-Navarro, Adriana Moreno-Rodríguez, Eyra Ortiz-Pérez, Gildardo Rivera
Förderung
- Secretaria de Investigacion y Posgrado del Instituto Politecnico Nacional
- Secretaría de Investigación y Posgrado del Instituto Politécnico Nacional
Zitieren
APA
Vázquez-Jiménez, L. K., González-González, A., Delgado-Maldonado, T., Gómez-Escobedo, R., Avalos-Navarro, G., Moreno-Rodríguez, A., Paz-González, A. D., Ortiz-Pérez, E., Nogueda-Torres, B., & Rivera, G. (2026). Using the Scaffold of FDA-Approved Drugs with Trypanocidal Activity to Identify New Anti-Trypanosoma cruzi Agents: An In Silico and In Vitro Approach. Molecules, 31(8), 1327. https://doi.org/10.3390/molecules31081327
Vancouver
Vázquez-Jiménez LK, González-González A, Delgado-Maldonado T, Gómez-Escobedo R, Avalos-Navarro G, Moreno-Rodríguez A, et al. Using the Scaffold of FDA-Approved Drugs with Trypanocidal Activity to Identify New Anti-Trypanosoma cruzi Agents: An In Silico and In Vitro Approach. Molecules. 2026;31(8):1327. doi:10.3390/molecules31081327
BibTeX
@article{VzquezJimnez2026,
author = {Vázquez-Jiménez, Lenci K and González-González, Alonzo and Delgado-Maldonado, Timoteo and Gómez-Escobedo, Rogelio and Avalos-Navarro, Guadalupe and Moreno-Rodríguez, Adriana and Paz-González, Alma D and Ortiz-Pérez, Eyra and Nogueda-Torres, Benjamín and Rivera, Gildardo},
title = {Using the Scaffold of FDA-Approved Drugs with Trypanocidal Activity to Identify New Anti-Trypanosoma cruzi Agents: An In Silico and In Vitro Approach},
journal = {Molecules},
year = {2026},
volume = {31},
number = {8},
pages = {1327},
doi = {10.3390/molecules31081327}
}
EUVIMED